The results showed that EGFR-TKI adjuvant treatment could significantly reduce the risk of death in patients with stage II-III NSCLC (HR, 0.65; 95% CI, 0.44–0.94; P = 0.022; Fig. 3C), when the ADAURA study was included. Here, EGFR is linked to non-small cell lung carcinoma.